{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:20:29Z","timestamp":1790965229638,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Nature Science Foundation of Chongqing","award":["cstc2021jcyj-msxmX0052"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0052"]}]},{"name":"the Chongqing Innovation Leading Talent Project","award":["CQYC20220303706"],"award-info":[{"award-number":["CQYC20220303706"]}]},{"name":"the Key Support Object of AMU","award":["410301060133"],"award-info":[{"award-number":["410301060133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06865-w","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:00:24Z","timestamp":1754406024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The CTSZ-TRA2A-IL32 axis defines a targetable macrophage-dependent pathway in metastatic prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Saipeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langlang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-128X","authenticated-orcid":false,"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"6865_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"6865_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jama.2023.26491","volume":"331","author":"BA Al Awamlh","year":"2024","unstructured":"Al Awamlh BA, Wallis CJ, Penson DF, Huang LC, Zhao Z, Conwill R, et al. Functional outcomes after localized prostate cancer treatment. JAMA. 2024;331:302\u201317.","journal-title":"JAMA"},{"key":"6865_CR3","doi-asserted-by":"publisher","first-page":"eadg2697","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9:eadg2697.","journal-title":"Sci Adv"},{"key":"6865_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.","journal-title":"Signal Transduct Target Ther"},{"key":"6865_CR5","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022;13:6036.","journal-title":"Nat Commun"},{"key":"6865_CR6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221007","volume":"220","author":"XF Li","year":"2023","unstructured":"Li XF, Selli C, Zhou HL, Cao J, Wu S, Ma RY, et al. Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med. 2023;220: e20221007.","journal-title":"J Exp Med"},{"key":"6865_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/08820139.2023.2258930","volume":"52","author":"H Jin","year":"2023","unstructured":"Jin H, Zhu J, Xuan R, Zhou Y, Xue B, Yang D, et al. A crosstalk between castration-resistant prostate cancer cells, M2 macrophages, and NK cells: role of the ATM-PI3K\/AKT-PD-L1 pathway. Immunol Invest. 2023;52:941\u201365.","journal-title":"Immunol Invest"},{"key":"6865_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semcancer.2014.05.001","volume":"31","author":"J Kos","year":"2015","unstructured":"Kos J, Vi\u017ein T, Fonovi\u0107 UP, Pi\u0161lar A. Intracellular signaling by cathepsin X: molecular mechanisms and diagnostic and therapeutic opportunities in cancer. Semin Cancer Biol. 2015;31:76\u201383.","journal-title":"Semin Cancer Biol"},{"key":"6865_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1101\/gad.249599.114","volume":"28","author":"L Akkari","year":"2014","unstructured":"Akkari L, Gocheva V, Kester JC, Hunter KE, Quick ML, Sevenich L, et al. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev. 2014;28:2134\u201350.","journal-title":"Genes Dev"},{"key":"6865_CR10","doi-asserted-by":"publisher","first-page":"D343","DOI":"10.1093\/nar\/gkr987","volume":"40","author":"ND Rawlings","year":"2012","unstructured":"Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucl Acid Res. 2012;40:D343-350.","journal-title":"Nucl Acid Res"},{"key":"6865_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1515\/BC.2005.136","volume":"386","author":"L Puzer","year":"2005","unstructured":"Puzer L, Cotrin SS, Cezari MHS, Hirata IY, Juliano MA, Stefe I, et al. Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L. Biol Chem. 2005;386:1191\u20135.","journal-title":"Biol Chem"},{"key":"6865_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3324\/haematol.2009.018671","volume":"95","author":"ND Staudt","year":"2010","unstructured":"Staudt ND, Aicher WK, Kalbacher H, Stevanovic S, Carmona AK, Bogyo M, et al. Cathepsin X is secreted by human osteoblasts, digests CXCL-12 and impairs adhesion of hematopoietic stem and progenitor cells to osteoblasts. Haematologica. 2010;95:1452\u201360.","journal-title":"Haematologica"},{"key":"6865_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024967","volume":"6","author":"J Wang","year":"2011","unstructured":"Wang J, Chen L, Li Y, Guan XY. Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS ONE. 2011;6: e24967.","journal-title":"PLoS ONE"},{"key":"6865_CR14","doi-asserted-by":"publisher","first-page":"1148635","DOI":"10.3389\/fonc.2023.1148635","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Zhou X, Li L, Ji L, Li J, Qu Y, et al. The association between CTSZ methylation in peripheral blood and breast cancer in Chinese women. Front Oncol. 2023;13:1148635.","journal-title":"Front Oncol"},{"key":"6865_CR15","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573-3587.e29.","journal-title":"Cell"},{"key":"6865_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. Doublet finder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8:329-337.e4.","journal-title":"Cell Syst"},{"key":"6865_CR17","doi-asserted-by":"publisher","first-page":"eaaz5764","DOI":"10.1126\/sciadv.aaz5764","volume":"6","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Wang R, Yu L, Sun H, Tian S, Li P, et al. Human TRA2A determines influenza A virus host adaptation by regulating viral mRNA splicing. Sci Adv. 2020;6:eaaz5764.","journal-title":"Sci Adv"},{"key":"6865_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrm2777","volume":"10","author":"M Chen","year":"2009","unstructured":"Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol. 2009;10:741\u201354.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6865_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12951-023-01986-0","volume":"21","author":"W Peng","year":"2023","unstructured":"Peng W, Xie Y, Luo Z, Liu Y, Xu J, Li C, et al. UTX deletion promotes M2 macrophage polarization by epigenetically regulating endothelial cell-macrophage crosstalk after spinal cord injury. J Nanobiotechnol. 2023;21:225.","journal-title":"J Nanobiotechnol"},{"key":"6865_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144016","volume":"131","author":"W Fu","year":"2021","unstructured":"Fu W, Hu W, Yi YS, Hettinghouse A, Sun G, Bi Y, et al. TNFR2\/14-3-3\u03b5 signaling complex instructs macrophage plasticity in inflammation and autoimmunity. J Clin Invest. 2021;131: e144016.","journal-title":"J Clin Invest"},{"key":"6865_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302909","volume":"10","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Peng S, Xu T, Liu J, Zhao L, Xu H, et al. Retinal microenvironment-protected Rhein-GFFYE nanofibers attenuate retinal ischemia-reperfusion injury via inhibiting oxidative stress and regulating microglial\/macrophage M1\/M2 polarization. Adv Sci (Weinh). 2023;10: e2302909.","journal-title":"Adv Sci (Weinh)"},{"key":"6865_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-024-01944-w","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Yu Z, Yang S, Liu Y, Song J, Mao J, et al. ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK\/PI3K\/AKT activation in a ceRNA manner. Mol Cancer. 2024;23:33.","journal-title":"Mol Cancer"},{"key":"6865_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1107\/S0907444902021479","volume":"59","author":"D Turk","year":"2003","unstructured":"Turk D, Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr. 2003;59:203\u201313.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"6865_CR24","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1074\/jbc.M112.352781","volume":"287","author":"N Bhutani","year":"2012","unstructured":"Bhutani N, Piccirillo R, Hourez R, Venkatraman P, Goldberg AL. Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes. J Biol Chem. 2012;287:17471\u201382.","journal-title":"J Biol Chem"},{"key":"6865_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.biocel.2009.02.019","volume":"41","author":"N Obermajer","year":"2009","unstructured":"Obermajer N, Doljak B, Jamnik P, Fonovi\u0107 UP, Kos J. Cathepsin X cleaves the c-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells. Int J Biochem Cell Biol. 2009;41:1685\u201396.","journal-title":"Int J Biochem Cell Biol"},{"key":"6865_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.intimp.2009.09.018","volume":"10","author":"DK N\u00e4gler","year":"2010","unstructured":"N\u00e4gler DK, Kraus S, Feierler J, Mentele R, Lottspeich F, Jochum M, et al. A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int Immunopharmacol. 2010;10:134\u20139.","journal-title":"Int Immunopharmacol"},{"key":"6865_CR27","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1074\/jbc.M110.185348","volume":"286","author":"T Ratovitski","year":"2011","unstructured":"Ratovitski T, Chighladze E, Waldron E, Hirschhorn RR, Ross CA. Cysteine proteases bleomycin hydrolase and cathepsin Z mediate n-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem. 2011;286:12578\u201389.","journal-title":"J Biol Chem"},{"key":"6865_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.02.025","volume":"174","author":"JT Hong","year":"2017","unstructured":"Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127\u201337.","journal-title":"Pharmacol Ther"},{"key":"6865_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104011","volume":"186","author":"JT Hough","year":"2023","unstructured":"Hough JT, Zhao L, Lequio M, Heslin AJ, Xiao H, Lewis CC, et al. IL-32 and its paradoxical role in neoplasia. Crit Rev Oncol Hematol. 2023;186: 104011.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6865_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10637-015-0320-9","volume":"34","author":"GA Cirkel","year":"2016","unstructured":"Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, et al. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Invest New Drugs. 2016;34:184\u201392.","journal-title":"Invest New Drugs"},{"key":"6865_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013;24:90\u20136.","journal-title":"Ann Oncol"},{"key":"6865_CR32","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","volume":"40","author":"F Pantano","year":"2021","unstructured":"Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, et al. Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene. 2021;40:1284\u201399.","journal-title":"Oncogene"},{"key":"6865_CR33","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/ijc.29165","volume":"136","author":"KJ Reeves","year":"2015","unstructured":"Reeves KJ, Hurrell JE, Cecchini M, van der Pluijm G, Down JM, Eaton CL, et al. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int J Cancer. 2015;136:1731\u201340.","journal-title":"Int J Cancer"},{"key":"6865_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-024-08290-3.","journal-title":"Nature"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06865-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:39:46Z","timestamp":1761043186000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06865-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6865"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06865-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The tumor tissue microarray of patients with prostate cancer used in this study was provided by Changsha Yaxiang Biotechnology Co., Ltd. This study was reviewed and approved by the Ethics Committee of the company (ethics approval number Csyayj2024022). The animal study was approved by the Animal Experiment Welfare and Ethics Committee of Army Medical University (AMUWEC20232943). All animal experiments were conducted in compliance with the requirements of Chinese microbiology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"865"}}